IcanoMAB is focusing on the development of new antibodies for the treatment of cancer, immune-system related diseases and COVID-19 in closed collaboration with Charles Dinarello.
‘IcanoMAB’s novel anti-IL-1R7 antibody blocks the signal transduction of IL-18. It helps to treat Cytokine-Release-Syndrome in COVID-19 late stage.’
Read More..
Increased IL-18, of IL-1 family, initiate the avalanche of effects in the Cytokine-Release-Syndrome, is known to correlate with the severity of late-stage COVID-19.Read More..
IcanoMAB’s novel anti-IL-1R7 (=IL-18 receptor beta chain) antibody blocks the signal transduction of pro-inflammatory IL-18. Pre-clinical Proof-of-Concept was provided and recently published by scientific partners at the Dinarello Lab, Department of Medicine, University of Colorado Denver, Aurora, Colorado/USA and Department of Medicine, the Radboud University Medical Center, Nijmegen/The Netherlands and the Department of Infectious Disease and Institute of Clinical Medicine Aarhus University Hospital, Aarhus/Denmark.
Other uses will include diseases related to the Cytokine-Release-Syndrome, e.g., Acute Respiratory Distress Syndrome (ARDS) and Macrophage Activation Syndrome (MAS) or other acute inflammatory diseases, e.g., IBD, Gout and Asthma.
Cytokine Hurricane in Lung may Damage Inflammatory Cells
Cytokine hurricane centered in the lungs drives respiratory symptoms in patients with severe COVID-19, a new study by immunologists at Columbia University Vagelos College of Physicians and Surgeons suggests.
Cytokine hurricane centered in the lungs drives respiratory symptoms in patients with severe COVID-19, a new study by immunologists at Columbia University Vagelos College of Physicians and Surgeons suggests.
Advertisement
